Results 1-10 of about 39|
  1. ... nlm.nih.gov/pubmed/25925619?tool=bestpractice.com Bruton kinase inhibitors Ibrutinib has been shown to have ... Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant ...
    Source: BMJ Best Practice
    Information Type: Oppslagsverk
  2. ... the B-cell tumour growth in concert with Bruton's tyrosine kinase (BTK) . [ 9] An MYD88-independent ... as monotherapy and in combination. Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, is approved in ...
    Source: BMJ Best Practice
    Information Type: Oppslagsverk
  3. ... the B-cell tumor growth in concert with Bruton tyrosine kinase (BTK) . [ 8] An MYD88-independent Sp1 ... as monotherapy and in combination. Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is approved for first- ...
    Source: BMJ Best Practice
    Information Type: Oppslagsverk
  4. ... isotypes with profoundly decreased or absent B cells • Bruton's tyrosine kinase (BTK) deficiency (mutation on the ... and Ig production; leads to X-linked agammaglobulinaemia/Bruton's disease) • Mu heavy-chain deficiency • Lambda-5 ...
    Source: BMJ Best Practice
    Information Type: Oppslagsverk
  5. ... isotypes with profoundly decreased or absent B cells • Bruton tyrosine kinase (BTK) deficiency (mutation on the BTK ... and Ig production; leads to X-linked agammaglobulinemia/Bruton disease) • Mu heavy-chain deficiency • Lambda-5 deficiency • ...
    Source: BMJ Best Practice
    Information Type: Oppslagsverk
  6. ... 420 mg orally once daily Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, is approved in ... 420 mg orally once daily Ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, is approved in ...
    Source: BMJ Best Practice
    Information Type: Oppslagsverk
  7. ... 420 mg orally once daily Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is approved for first- ... 420 mg orally once daily Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is approved for first- ...
    Source: BMJ Best Practice
    Information Type: Oppslagsverk
  8. ... refractory NHL and chronic lymphocytic leukaemia (CLL) . [ 133] Bruton kinase inhibitors Ibrutinib has been shown to have ... given promising early results. Acalabrutinib, a second-generation bruton kinase inhibitor, has been granted FDA accelerated approval ...
    Source: BMJ Best Practice
    Information Type: Oppslagsverk
  9. ... or early childhood) suggest X-linked agammaglobulinaemia (XLA/Bruton's disease). Maternal immunoglobulins (IgG) are transferred to ... common); tonsillar tissue (tonsils are small/absent with Bruton's disease); fungal nail changes; eczema (may be ...
    Source: BMJ Best Practice
    Information Type: Oppslagsverk
  10. ... or early childhood) suggest X-linked agammaglobulinemia (XLA/Bruton disease). Maternal immunoglobulins (IgG) are transferred to the ... common); tonsillar tissue (tonsils are small/absent with Bruton disease); fungal nail changes; eczema (may be seen ...
    Source: BMJ Best Practice
    Information Type: Oppslagsverk
first · previous · 1 · 2 · 3 · 4 · next · last